Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Parkinson Disease: HELP
Articles from Spain
Based on 1,265 articles published since 2008
||||

These are the 1265 published articles about Parkinson Disease that originated from Spain during 2008-2019.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: Consensus from an international survey and discussion program. 2015

Odin, P / Ray Chaudhuri, K / Slevin, J T / Volkmann, J / Dietrichs, E / Martinez-Martin, P / Krauss, J K / Henriksen, T / Katzenschlager, R / Antonini, A / Rascol, O / Poewe, W / Anonymous2260838. ·Department of Neurology, Lund University Hospital, 221 85 Lund, Sweden; Klinikum-Bremerhaven, D-27574 Bremerhaven, Germany. Electronic address: per.odin@med.lu.se. · King's College London, and National Parkinson Foundation Centre of Excellence, Dept of Neurology, King's College Hospital, London, UK. · Department of Neurology, University of Kentucky College of Medicine, Kentucky Clinic L-445, 740 South Limestone Street, Lexington, KY 40536-0284, USA. · Department of Neurology, University Hospital of Würzburg, 97080 Würzburg, Germany. · Department of Neurology, Oslo University Hospital and University of Oslo, N-0424 Oslo, Norway. · National Center for Epidemiology and CIBERNED, ISCIII, Avenida Monforte de Lemos 5, 28029 Madrid, Spain. · Department of Neurosurgery, Medizinische Hochschule Hannover, Carl-Neuberg-Strasse 1, 30625 Hannover, Germany. · University Hospital of Bispebjerg, Bispebjerg Bakke 23, 2400 København, NV, Denmark. · Department of Neurology and Karl Landsteiner Institute for Neuroimmunological and Neurodegenerative Disorders, Sozialmedizinisches Zentrum Ost - Donauspital, 1220 Wien Langobardenstraße 122, Austria. · Parkinson and Movement Disorders Unit, IRCCS Hospital San Camillo, Venice, Italy. · Clinical Investigation Center 1436 and Department of Clinical Pharmacology, INSERM and University Hospital of Toulouse, Toulouse University, 37 alées Jules Giesde, 31000 Toulouse, France; Clinical Investigation Center 1436 and Department of Neurosciences, INSERM and University Hospital of Toulouse, Toulouse University, 37 alées Jules Giesde, 31000 Toulouse, France. · Innsbruck Medical University/University Hospital, Anichstrasse 35, A-6020 Innsbruck, Austria. ·Parkinsonism Relat Disord · Pubmed #26233582.

ABSTRACT: Navigate PD was an educational program established to supplement existing guidelines and provide recommendations on the management of Parkinson's disease (PD) refractory to oral/transdermal therapies. It involved 103 experts from 13 countries overseen by an International Steering Committee (ISC) of 13 movement disorder specialists. The ISC identified 71 clinical questions important for device-aided management of PD. Fifty-six experts responded to a web-based survey, rating 15 questions as 'critically important;' these were refined to 10 questions by the ISC to be addressed through available evidence and expert opinion. Draft guidance was presented at international/national meetings and revised based on feedback. Key take-home points are: • Patients requiring levodopa >5 times daily who have severe, troublesome 'off' periods (>1-2 h/day) despite optimal oral/transdermal levodopa or non-levodopa-based therapies should be referred for specialist assessment even if disease duration is <4 years. • Cognitive decline related to non-motor fluctuations is an indication for device-aided therapies. If cognitive impairment is mild, use deep brain stimulation (DBS) with caution. For patients who have cognitive impairment or dementia, intrajejunal levodopa infusion is considered as both therapeutic and palliative in some countries. Falls are linked to cognitive decline and are likely to become more frequent with device-aided therapies. • Insufficient control of motor complications (or drug-resistant tremor in the case of DBS) are indications for device-aided therapies. Levodopa-carbidopa intestinal gel infusions or subcutaneous apomorphine pump may be considered for patients aged >70 years who have mild or moderate cognitive impairment, severe depression or other contraindications to DBS.

2 Editorial Editorial: Proteomic alterations by mutations involved in Parkinson's disease and related disorders. 2017

Cardona, F / Perez-Tur, J. ·Instituto de Biomedicina de Valencia Consejo Superior de Investigaciones Científicas (IBV-CSIC) Calle Jaime Roig 11 Valencia E46010, Spain. ·Curr Protein Pept Sci · Pubmed #28879817.

ABSTRACT: -- No abstract --

3 Editorial What would Dr. James Parkinson think today? The 21st Annual Congress of the International Parkinson's disease and movement disorders society. 2017

Obeso, Jose A / Trenkwalder, Claudia. ·HM CINAC, HM Puerta del Sur, and CEU-San Pablo University, Madrid. CIBERNED, Institute Carlos III, Spain. · Department of Neurosurgery, University Medical Center, Goettingen, and Paracelsus-Elena Hospital, Kassel, Germany. ·Mov Disord · Pubmed #28712120.

ABSTRACT: -- No abstract --

4 Editorial What Would Dr. James Parkinson Think Today? I. The Role of Functional Neurosurgery for Parkinson's Disease. 2017

Hariz, Marwan / Obeso, Jose A. ·UCL-Institute of Neurology, London, United Kingdom. · Department of Clinical Neuroscience, Umeå University, Umeå, Sweden. · CINAC-HM Puerta del Sur, Mostoles and CEU-San Pablo University, Madrid, Spain. · CIBERNED, Insituto Carlos III, Madrid, Spain. ·Mov Disord · Pubmed #28124429.

ABSTRACT: -- No abstract --

5 Editorial Functions of the basal ganglia-paradox or no paradox? 2016

Crossman, Alan R / Obeso, Jose A. ·University of Manchester, Manchester, UK. · HM CINAC, HM Puerta del Sur, Mostoles, Madrid, Universidad CEU San Pablo, Madrid, Spain. · Center for Networked Biomedical Research on Neurodegenerative Diseases, Madrid, Spain. ·Mov Disord · Pubmed #27506637.

ABSTRACT: -- No abstract --

6 Editorial Advances in sensor and wearable technologies for Parkinson's disease. 2016

Sánchez-Ferro, Álvaro / Maetzler, Walter. ·HM CINAC, Hospital Universitario HM Puerta del Sur, Móstoles, Madrid, Spain. · Research Laboratory of Electronics, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA. · Center for Neurology and Hertie Institute for Clinical Brain Research, Department of Neurodegeneration, University of Tübingen, Tübingen, Germany. walter.maetzler@uni-tuebingen.de. · German Center for Neurodegenerative Diseases, Tübingen, Germany. walter.maetzler@uni-tuebingen.de. ·Mov Disord · Pubmed #27477675.

ABSTRACT: -- No abstract --

7 Editorial The 'parkinsonian heart': a diagnostic and prognostic tool. 2015

Muxí, África. ·Nuclear Medicine Department, Hospital Clínic Barcelona, Barcelona, Spain Institut d'Investigacions Biomèdiques August Pí i Sunyer (IDIBAPS), Barcelona, Spain Universitat de Barcelona, Barcelona, Spain. ·J Neurol Neurosurg Psychiatry · Pubmed #25986366.

ABSTRACT: -- No abstract --

8 Editorial DaTscan and Parkinson's disease: DAT binding should not lead to binding decisions in clinical practice. 2014

de la Fuente-Fernández, R / Lövblad, K-O. ·Complejo Hospitalario Universitario de Ferrol (CHUF), Section of Neurology, Hospital A. Marcide, Ferrol, Spain. raul.delafuente@sen.es. ·Eur J Neurol · Pubmed #24837615.

ABSTRACT: -- No abstract --

9 Editorial Nonmotor symptoms and health-related quality of life in early Parkinson's disease. 2014

Martinez-Martin, Pablo. ·Research Unit, Alzheimer Center Reina Sofía Foundation; Section of Neuroepidemiology, National Center for Epidemiology; and Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Carlos III Institute of Health, Madrid, Spain. ·Mov Disord · Pubmed #24375626.

ABSTRACT: -- No abstract --

10 Review Neuroprotective effects of phytochemicals on dopaminergic neuron cultures. 2019

Sandoval-Avila, S / Diaz, N F / Gómez-Pinedo, U / Canales-Aguirre, A A / Gutiérrez-Mercado, Y K / Padilla-Camberos, E / Marquez-Aguirre, A L / Díaz-Martínez, N E. ·Unidad de Biotecnología Médica y Farmacéutica, Centro de Investigación y Asistencia en Tecnología y Diseño del Estado de Jalisco, Guadalajara, Jalisco, México. · Departamento de Biología Celular, Instituto Nacional de Perinatología, Ciudad de México, México. · Instituto de Neurociencias, IdISSC, Hospital Clínico San Carlos, Universidad Complutense, Madrid, España. · Unidad de Biotecnología Médica y Farmacéutica, Centro de Investigación y Asistencia en Tecnología y Diseño del Estado de Jalisco, Guadalajara, Jalisco, México. Electronic address: ediaz@ciatej.mx. ·Neurologia · Pubmed #27342389.

ABSTRACT: INTRODUCTION: Parkinson's disease is a progressive neurodegenerative disorder characterised by a loss of dopaminergic neurons in the substantia nigra pars compacta, which results in a significant decrease in dopamine levels and consequent functional motor impairment. DEVELOPMENT: Although its aetiology is not fully understood, several pathogenic mechanisms, including oxidative stress, have been proposed. Current therapeutic approaches are based on dopamine replacement drugs; these agents, however, are not able to stop or even slow disease progression. Novel therapeutic approaches aimed at acting on the pathways leading to neuronal dysfunction and death are under investigation. CONCLUSIONS: In recent years, such natural molecules as polyphenols, alkaloids, and saponins have been shown to have a neuroprotective effect due to their antioxidant and anti-inflammatory properties. The aim of our review is to analyse the most relevant studies worldwide addressing the benefits of some phytochemicals used in in vitro models of Parkinson's disease.

11 Review Pharmacoepigenomic Interventions as Novel Potential Treatments for Alzheimer's and Parkinson's Diseases. 2018

Teijido, Oscar / Cacabelos, Ramón. ·EuroEspes Biomedical Research Center, Institute of Medical Science and Genomic Medicine, 15165 La Coruña, Spain. epigenetica@euroespes.com. · EuroEspes Biomedical Research Center, Institute of Medical Science and Genomic Medicine, 15165 La Coruña, Spain. rcacabelos@euroespes.com. · Chair of Genomic Medicine, Continental University Medical School, Huancayo 12000, Peru. rcacabelos@euroespes.com. ·Int J Mol Sci · Pubmed #30332838.

ABSTRACT: Cerebrovascular and neurodegenerative disorders affect one billion people around the world and result from a combination of genomic, epigenomic, metabolic, and environmental factors. Diagnosis at late stages of disease progression, limited knowledge of gene biomarkers and molecular mechanisms of the pathology, and conventional compounds based on symptomatic rather than mechanistic features, determine the lack of success of current treatments, including current FDA-approved conventional drugs. The epigenetic approach opens new avenues for the detection of early presymptomatic pathological events that would allow the implementation of novel strategies in order to stop or delay the pathological process. The reversibility and potential restoring of epigenetic aberrations along with their potential use as targets for pharmacological and dietary interventions sited the use of epidrugs as potential novel candidates for successful treatments of multifactorial disorders involving neurodegeneration. This manuscript includes a description of the most relevant epigenetic mechanisms involved in the most prevalent neurodegenerative disorders worldwide, as well as the main potential epigenetic-based compounds under investigation for treatment of those disorders and their limitations.

12 Review Peripheral and central autonomic nervous system: does the sympathetic or parasympathetic nervous system bear the brunt of the pathology during the course of sporadic PD? 2018

Orimo, Satoshi / Ghebremedhin, Estifanos / Gelpi, Ellen. ·Department of Neurology, Kanto Central Hospital, 6-25-1 Kami-Yoga, Setagaya-ku, Tokyo, 158-8531, Japan. orimo@kanto-ctr-hsp.com. · Institute of Clinical Neuroanatomy, J. W. Goethe-University, Theodor-Stern-Kai 7, 60590, Frankfurt/Main, Germany. · Neurological Tissue Bank of the Biobank-Hospital Clinic-IDIBAPS, Barcelona, Spain. · Institute of Neurology, Medical University of Vienna, Vienna, Austria. ·Cell Tissue Res · Pubmed #29869180.

ABSTRACT: It is a well-established fact that the sympathetic, parasympathetic and enteric nervous systems are affected at early stages in Parkinson's disease (PD). However, it is not yet clarified whether the earliest pathological events preferentially occur in any of these three divisions of the autonomic nervous system (ANS). Significant involvement of the peripheral autonomic nervous system of the heart and gastrointestinal tract has been documented in PD. Accumulating evidence suggests that the PD pathology spreads centripetally from the peripheral to central nervous system through autonomic nerve fibers, implicating the ANS as a major culprit in PD pathogenesis and a potential target for therapy. This study begins with a brief overview of the structures of the central and peripheral autonomic nervous system and then outlines the major clinicopathological manifestations of cardiovascular and gastrointestinal disturbances in PD.

13 Review Neurorehabilitation in Parkinson's Disease: A Critical Review of Cognitive Rehabilitation Effects on Cognition and Brain. 2018

Díez-Cirarda, María / Ibarretxe-Bilbao, Naroa / Peña, Javier / Ojeda, Natalia. ·Department of Methods and Experimental Psychology, Faculty of Psychology and Education, University of Deusto, Bilbao, Spain. ·Neural Plast · Pubmed #29853840.

ABSTRACT: Background: Parkinson's disease (PD) patients experience cognitive impairment which has been related to reduced quality of life and functional disability. These symptoms usually progress until dementia occurs. Some studies have been published assessing the efficacy of cognitive treatments on improving cognition, functional outcome, and producing changes in brain activity. Objective: A critical review was performed to present up-to-date neurorehabilitation effects of cognitive rehabilitation in PD, with special emphasis on the efficacy on cognition, quality of life aspects, brain changes, and the longitudinal maintenance of these changes. Results: After exclusions, 13 studies were reviewed, including 6 randomized controlled trials for the efficacy on cognition, 2 randomized controlled trials regarding the brain changes after cognitive training, and 5 studies which evaluated the long-term effects of cognitive treatments. Conclusions: Cognitive rehabilitation programs have demonstrated to be effective on improving cognitive functions, but more research is needed focusing on the efficacy on improving behavioral aspects and producing brain changes in patients with PD. Moreover, there is a need of randomized controlled trials with long-term follow-up periods.

14 Review Clinical utility of FDG PET in Parkinson's disease and atypical parkinsonism associated with dementia. 2018

Walker, Zuzana / Gandolfo, Federica / Orini, Stefania / Garibotto, Valentina / Agosta, Federica / Arbizu, Javier / Bouwman, Femke / Drzezga, Alexander / Nestor, Peter / Boccardi, Marina / Altomare, Daniele / Festari, Cristina / Nobili, Flavio / Anonymous2310976. ·Division of Psychiatry, University College London, London, UK. z.walker@ucl.ac.uk. · St Margaret's Hospital, Essex Partnership University NHS Foundation Trust, Epping, CM16 6TN, UK. z.walker@ucl.ac.uk. · Alzheimer Operative Unit, IRCCS S. Giovanni di Dio, Fatebenefratelli, Brescia, Italy. · Division of Nuclear Medicine and Molecular Imaging, Department of Medical Imaging, University Hospitals of Geneva, Geneva University, Geneva, Switzerland. · Neuroimaging Research Unit, Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy. · Department of Nuclear Medicine, Clinica Universidad de Navarra, University of Navarra, Pamplona, Spain. · Department of Neurology & Alzheimer Center, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, The Netherlands. · Department of Nuclear Medicine, University Hospital of Cologne, University of Cologne and German Center for Neurodegenerative Diseases (DZNE), Cologne, Germany. · German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany. · Queensland Brain Institute, University of Queensland and the Mater Hospital, Brisbane, Australia. · LANVIE (Laboratoire de Neuroimagerie du Vieillissement), Department of Psychiatry, University of Geneva, Geneva, Switzerland. · LANE - Laboratory of Alzheimer's Neuroimaging & Epidemiology, IRCCS S. Giovanni di Dio, Fatebenefratelli, Brescia, Italy. · Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy. · Department of Neuroscience (DINOGMI), University of Genoa & Clinical Neurology Polyclinic IRCCS San Martino-IST, Genoa, Italy. flaviomariano.nobili@hsanmartino.it. ·Eur J Nucl Med Mol Imaging · Pubmed #29779045.

ABSTRACT: PURPOSE: There are no comprehensive guidelines for the use of FDG PET in the following three clinical scenarios: (1) diagnostic work-up of patients with idiopathic Parkinson's disease (PD) at risk of future cognitive decline, (2) discriminating idiopathic PD from progressive supranuclear palsy, and (3) identifying the underlying neuropathology in corticobasal syndrome. METHODS: We therefore performed three literature searches and evaluated the selected studies for quality of design, risk of bias, inconsistency, imprecision, indirectness and effect size. Critical outcomes were the sensitivity, specificity, accuracy, positive/negative predictive value, area under the receiving operating characteristic curve, and positive/negative likelihood ratio of FDG PET in detecting the target condition. Using the Delphi method, a panel of seven experts voted for or against the use of FDG PET based on published evidence and expert opinion. RESULTS: Of 91 studies selected from the three literature searches, only four included an adequate quantitative assessment of the performance of FDG PET. The majority of studies lacked robust methodology due to lack of critical outcomes, inadequate gold standard and no head-to-head comparison with an appropriate reference standard. The panel recommended the use of FDG PET for all three clinical scenarios based on nonquantitative evidence of clinical utility. CONCLUSION: Despite widespread use of FDG PET in clinical practice and extensive research, there is still very limited good quality evidence for the use of FDG PET. However, in the opinion of the majority of the panellists, FDG PET is a clinically useful imaging biomarker for idiopathic PD and atypical parkinsonism associated with dementia.

15 Review Update in therapeutic strategies for Parkinson's disease. 2018

Kulisevsky, Jaime / Oliveira, Lais / Fox, Susan H. ·Movement Disorders Unit, Neurology Department, Sant Pau Hospital (IIB Sant Pau), Universitat Autònoma de Barcelona, CIBERNED, Universitat Oberta de Catalunya, Barcelona, Spain. · Edmond J. Safra Program in Parkinson's Disease and The Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada. ·Curr Opin Neurol · Pubmed #29746402.

ABSTRACT: PURPOSE OF REVIEW: To review recent advances in therapeutics for motor and nonmotor symptoms of Parkinson's disease. RECENT FINDINGS: Neuroprotection remains a large area of investigation with preliminary safety data on alpha synuclein immunotherapy and glucagon-like peptide-1 agonists. Novel Monoamine Oxidase B and Caetchol-O-methyltransferase-inhibitors for motor fluctuations have shown benefit and are recently approved for clinical use. Long-acting amantadine has also been approved to reduce dyskinesia. Alternative delivery strategies (sublingual, inhaled) dopaminergics may prove useful for rapid reversal of Parkinson's disease motor symptoms. Advanced therapies (surgery and infusional therapies) continue to be useful in subgroups of patients for motor complications with improved safety and also benefit on some nonmotor symptoms, including neuropsychiatric issues. Specific therapeutics for cognition, swallowing, sleep, and mood disorders had moderate to limited benefits. Exercise-based therapy appears beneficial at all stages of Parkinson's disease. SUMMARY: The motor symptoms of Parkinson's disease can be reasonably treated and managed. However, therapies to slow or prevent disease progression remain a focus of research. Despite increased studies, treating nonmotor symptoms remains a challenge and an ongoing priority.

16 Review The Promise of Telemedicine for Movement Disorders: an Interdisciplinary Approach. 2018

Ben-Pazi, H / Browne, P / Chan, P / Cubo, E / Guttman, M / Hassan, A / Hatcher-Martin, J / Mari, Z / Moukheiber, E / Okubadejo, N U / Shalash, A / Anonymous1401121. ·Neuropediatric unit, Shaare Zedek Medical Center, Jerusalem, Israel. · Neurology Department, University Hospital Galway, Newcastle Road, Galway, Ireland. · School of Medicine, National University of Ireland Galway, Galway, Ireland. · Department of Neurobiology, Neurology and Geriatrics, Xuanwu Hospital of Capital Medical University Beijing, Beijing, China. · Neurology Department, University Hospital, Burgos, Spain. mcubo@saludcastillayleon.es. · University of Toronto, Toronto, ON, Canada. · Department of Neurology, Mayo Clinic, Rochester, MN, USA. · Movement Disorders Program, Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA. · Parkinson's Disease and Movement Disorders Program, Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, USA. · Department of Neurology, Johns Hopkins Medicine, Baltimore, MD, USA. · Neurology Unit, Department of Medicine, College of Medicine, University of Lagos, Lagos State, Nigeria. · Department of Neurology, Faculty of Medicine, Ain Shams University, Cairo, Egypt. ·Curr Neurol Neurosci Rep · Pubmed #29654523.

ABSTRACT: PURPOSE OF REVIEW: Advances in technology have expanded telemedicine opportunities covering medical practice, research, and education. This is of particular importance in movement disorders (MDs), where the combination of disease progression, mobility limitations, and the sparse distribution of MD specialists increase the difficulty to access. In this review, we discuss the prospects, challenges, and strategies for telemedicine in MDs. RECENT FINDINGS: Telemedicine for MDs has been mainly evaluated in Parkinson's disease (PD) and compared to in-office care is cost-effective with similar clinical care, despite the barriers to engagement. However, particular groups including pediatric patients, rare MDs, and the use of telemedicine in underserved areas need further research. Interdisciplinary telemedicine and tele-education for MDs are feasible, provide similar care, and reduce travel costs and travel time compared to in-person visits. These benefits have been mainly demonstrated for PD but serve as a model for further validation in other movement disorders.

17 Review Dopaminergic Neuroprotection with Atremorine in Parkinson´s Disease. 2018

Carrera, Ivan / Fernandez-Novoa, Lucia / Sampedro, Carolina / Tarasov, Vadim V / Aliev, Gjumrakch / Cacabelos, Ramon. ·Health Biotechnology, EuroEspes Biotechnology, Corunna, Spain. · Sechenov First Moscow State Medical University, 119991, Moscow, Russian Federation. · Gally International Biomedical Research LLC, San Antonio, Texas, United States. · University of Atlanta, John Greek , GA, United States. · Institute of Physiologically Active Compounds, Russian Academy of Sciences, Chernogolovka, 142432, Russian Federation. · EuroEspes Biomedical Research Center, Institute for CNS Disorders and Genomic Medicine, Corunna, Spain. ·Curr Med Chem · Pubmed #29637853.

ABSTRACT: Patients with Parkinson's disease (PD) are looking forward to new therapeutic strategies that may gradually decelerate the rate of neurodegenerative decline, associated with mobility restrictions and related morbidity. Its continuous neurodegenerative process, exacerbated by genetic mutations or environmental toxins, involves a progressive reduction in the dopamine neurotransmission levels, synaptic uptake density, oxidative glucose intake, deficient striatal lactate accumulation and chronic inflammation. Over the last decade, novel bioproducts have received considerable interest due to their unique potential of unifying nutritional, safety and therapeutic natural effects. Some nutraceuticals play a crucial role in the control of the signaling transduction pathways in neurotransmission and inflammation affected in PD, and some natural compounds can beneficially interact with each one of these biological mechanisms to slow down disease progression. Atremorine, a novel plant-derived nutraceutical, probably with a neuroprotective effect in the dopaminergic neurons of the substantia nigra (pars compacta), is a prototype of this new category of bioproducts with potential effects in PD. The major focus of this review will be on the current knowledge and biomedical investigation strategies through a plant-derived neuroprotective approach to improve life quality in PD patients, being of paramount importance for health providers, caregivers and the patients themselves.

18 Review Pain in Parkinson's disease: facts and uncertainties. 2018

Antonini, A / Tinazzi, M / Abbruzzese, G / Berardelli, A / Chaudhuri, K R / Defazio, G / Ferreira, J / Martinez-Martin, P / Trenkwalder, C / Rascol, O. ·University of Padua, Padua. · University of Verona, Verona. · University of Genoa, Genoa. · University of Rome, Rome. · IRCCS NEUROMED, Isernia, Italy. · Kings College London, London, UK. · University of Cagliari, Cagliari, Italy. · Hospital de Santa Maria, Lisbon, Portugal. · National Center of Epidemiology and CIBERNED, Madrid, Spain. · University Medical Center Goettingen, Goettingen, Germany. · Université de Toulouse, Toulouse, France. ·Eur J Neurol · Pubmed #29520899.

ABSTRACT: Pain is one of the most common and troublesome non-motor symptoms of Parkinson's disease (PD). It can appear at any time during the disease and is often present before diagnosis. However, there is little or no consensus on its definition. An expert group of clinicians with relevant research experience met to review the existing evidence and to identify gaps in our understanding leading towards AUTHOR: 'understanding towards' has been changed to 'understanding leading towards'. Please check and confirm that this is appropriate an optimized therapy of pain in PD. Key findings from epidemiologic, neurophysiologic, neuroimaging and clinical studies are reviewed. In each case, the evidence base is limited by wide variations in the definitions of pain applied, study methodologies and populations evaluated. Disease-related and medical conditions trigger spontaneous pain in patients with PD, which is then abnormally processed and results in painful manifestations in specific body parts. Dopaminergic medications, such as rotigotine, as well as opiate analgesics, such as oxycodone, have shown positive results but future studies with more detailed pain characterization at inclusion are warranted.

19 Review Update on visual function and choroidal-retinal thickness alterations in Parkinson's disease. 2018

Obis, J / Satue, M / Alarcia, R / Pablo, L E / Garcia-Martin, E. ·Departamento de Oftalmología, Hospital Universitario Miguel Servet, Zaragoza, España. Electronic address: jobal89@hotmail.com. · Departamento de Oftalmología, Hospital Universitario Miguel Servet, Zaragoza, España. ·Arch Soc Esp Oftalmol · Pubmed #29454631.

ABSTRACT: Parkinson's disease (PD) is a neurodegenerative process that affects 7.5 million people around the world. Since 2004, several studies have demonstrated changes in various retinal layers in PD using optical coherence tomography (OCT). However, there are some discrepancies in the results of those studies. Some of them have correlated retinal thickness with the severity or duration of the disease, demonstrating that OCT measurements may be an innocuous and easy biomarker for PD progression. Other studies have demonstrated visual dysfunctions since early phases of the disease. Lastly, the most recent studies that use Swept Source OCT technology, have found choroidal thickness increase in PD patients and provide new information related to the retinal degenerative process in this disease. The aim of this paper is to review the literature on OCT and PD, in order to determine the altered retinal and choroidal parameters in PD and their possible clinical usefulness, and also the visual dysfunctions with higher impact in these patients.

20 Review [Epidemiology of Parkinson's disease in Spain and its contextualisation in the world]. 2018

Benito-Leon, J. ·Hospital Universitario 12 de Octubre , Madrid, Espana. ·Rev Neurol · Pubmed #29435969.

ABSTRACT: INTRODUCTION: The study of the epidemiology of Parkinson's disease (PD) is essential because it is a public health problem and because the differences in its prevalence and incidence offer clues as to the existence of aetiologically important environmental or biological factors. AIMS: To report the most relevant data about the descriptive epidemiology (prevalence, incidence and mortality) of PD from studies conducted in different countries, with special emphasis on those carried out in Spain and Latin America. Likewise, the study also includes a discussion of some of the main risk factors or protectors of this disease (analytical epidemiology) that have emerged thanks to the data obtained from large cohorts in the literature. DEVELOPMENT: We conduct an analysis of the most significant population-based studies, focusing especially on those conducted using the 'door-to-door' methodology. CONCLUSIONS: Its prevalence and incidence vary greatly around the world. In general, prevalence is higher in Europe and the United States than in other countries and is relatively uniform, fluctuating over a range that is not very noteworthy. In Asian, Latin American and African countries it is lower, especially in this last continent. These differences could be partly due to the specific factors of the population studied (that is to say, higher mortality rate due to lower economic resources). The most firmly established risk factors are ageing and being male.

21 Review Parasomnias and Sleep-Related Movement Disorders in Older Adults. 2018

Iranzo, Alex. ·Neurology Service, Multidisciplinary Sleep Unit, Hospital Clinic de Barcelona, C/ Villarroel 180, Barcelona 08036, Spain. Electronic address: AIRANZO@clinic.cat. ·Sleep Med Clin · Pubmed #29412983.

ABSTRACT: Parasomnias and sleep-related movement disorders are important problems in older adults. Sleep paralysis is rare, but may occur in families. In a minority of patients with disorders of arousal, the episodes persist until the age of 70. Zolpidem and other medications may induce sleepwalking and sleep-related eating. Most patients with idiopathic rapid eye movement (REM) sleep behavior disorder eventually develop Parkinson's disease or dementia with Lewy bodies. Anti-IgLON5 disease includes abnormal behaviors in NREM and REM sleep. Restless legs syndrome prevalence increases with age. A severe form of periodic limb movements in sleep may mimic REM sleep behavior disorder.

22 Review Novel models for Parkinson's disease and their impact on future drug discovery. 2018

Trigo-Damas, Ines / Del Rey, Natalia Lopez-Gonzalez / Blesa, Javier. ·a HM CINAC, Hospital Universitario HM Puerta del Sur , Móstoles , Spain. · b CIBERNED , Instituto Carlos III , Madrid , Spain. ·Expert Opin Drug Discov · Pubmed #29363335.

ABSTRACT: INTRODUCTION: Parkinson's disease is a progressive neurodegenerative disease that affects millions of elderly individuals worldwide. Despite intensive efforts dedicated to find a better treatment, the pathogenesis of Parkinson's Disease remains unknown. In search for a better therapy for the disease, several new in vivo and in vitro models of Parkinson´s disease have been developed in recent times. Areas covered: The authors provide an outline of the various traditional models of Parkinson´s disease and address those that have been recently generated. They also discuss the utility of these models for the identification of drugs of potential therapeutic value for Parkinson´s Disease patients. From the cell based models and the well-known toxin-based animal models, to the recent genetic models and the increasingly used non-mammalian models, every model is worthwhile in the search for a better Parkinson´s Disease therapy. Expert opinion: Almost 60 years after its discovery, levodopa is still the gold standard treatment for Parkinson's Disease patients. It seems unlikely that a single model can fully recapitulate the complexity of Parkinson's Disease in the same way it appears improbable that a unique treatment could relieve both the motor and non-motor symptoms of Parkinson's Disease altogether. Therefore treatment will probably require a combination of therapies.

23 Review Comprehensive grading of Parkinson's disease using motor and non-motor assessments: addressing a key unmet need. 2018

Martinez-Martin, Pablo / Ray Chaudhuri, Kallol. ·a National Center of Epidemiology and CIBERNED , Carlos III Institute of Health , Madrid , Spain. · b National Parkinson Foundation International Centre of Excellence , King's College London and King's College Hospital , London , UK. · c The Maurice Wohl Clinical Neuroscience Institute , King's College London , London , UK. ·Expert Rev Neurother · Pubmed #29090594.

ABSTRACT: INTRODUCTION: Parkinson's disease (PD) is expressed through motor and non-motor symptoms (NMS) that differ considerably in presence and severity among patients and over time. Furthermore, the progression pattern of the NMS does not necessarily parallel the course of the motor impairment. Gradation of PD according to the motor impairment and burden of NMS is an unmet need for an appropriate management of patients. Areas covered: A review of the studies on clinical gradation methods applied to PD is carried out in this article. Studies have provided cut-off values for a pragmatic classification of scores from rating scales and questionnaires in mild, moderate, and severe PD, considering motor state, complications, disability, and NMS. Grading systems with Hoehn and Yahr staging, Clinical Impression of Severity Index for PD, NMS Scale, NMS Questionnaire, and MDS-UPDRS, are available. These systems are reviewed in detail and examples in format of simple cards are presented. Expert commentary: Patients can be adequately assessed and properly managed according to their specific needs. A comprehensive method for gradation of PD manifestations severity is, therefore, desirable. In the absence of objective in vivo biomarkers for quantitative standardized information, scale-based clinical gradation systems provide a suitable alternative.

24 Review Sex differences in Parkinson's disease: Features on clinical symptoms, treatment outcome, sexual hormones and genetics. 2018

Jurado-Coronel, Juan Camilo / Cabezas, Ricardo / Ávila Rodríguez, Marco Fidel / Echeverria, Valentina / García-Segura, Luis Miguel / Barreto, George E. ·Departamento de Nutrición y Bioquímica, Facultad de Ciencias, Pontificia Universidad Javeriana, Bogotá D.C., Colombia. · Facultad de Ciencias de la Salud, Universidad del Tolima, Ibagué, Colombia. · Universidad San Sebastián, Fac. Cs de la Salud, Lientur 1457, Concepción, 4080871, Chile; Research & Development Service, Bay Pines VA Healthcare System, Bay Pines, FL 33744, USA. · Instituto Cajal, CSIC, Madrid, Spain; CIBER de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES), Instituto de Salud Carlos III, Madrid, Spain. · Departamento de Nutrición y Bioquímica, Facultad de Ciencias, Pontificia Universidad Javeriana, Bogotá D.C., Colombia; Instituto de Ciencias Biomédicas, Universidad Autónoma de Chile, Santiago, Chile. Electronic address: gsampaio@javeriana.edu.co. ·Front Neuroendocrinol · Pubmed #28974386.

ABSTRACT: Parkinson's disease (PD) is the second most frequent age-related neurodegenerative disorder. Sex is an important factor in the development of PD, as reflected by the fact that it is more common in men than in women by an approximate ratio of 2:1. Our hypothesis is that differences in PD among men and women are highly determined by sex-dependent differences in the nigrostriatal dopaminergic system, which arise from environmental, hormonal and genetic influences. Sex hormones, specifically estrogens, influence PD pathogenesis and might play an important role in PD differences between men and women. The objective of this review was to discuss the PD physiopathology and point out sex differences in nigrostriatal degeneration, symptoms, genetics, responsiveness to treatments and biochemical and molecular mechanisms among patients suffering from this disease. Finally, we discuss the role estrogens may have on PD sex differences.

25 Review Two-hundred Years Later: Is Parkinson's Disease a Single Defined Entity? 2017

Rodríguez-Violante, Mayela / Cervantes-Arriaga, Amin / Fahn, Stanley / Tolosa, Eduardo. ·Movement Disorders Clinic, National Institute of Neurology and Neurosurgery, Mexico City, Mexico, USA. · Department of Neurology, Columbia University Medical Center, New York, USA. · Neurological Tissue Bank, Hospital Clinic-Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Madrid and Universidad de Barcelona, Barcelona, Spain. ·Rev Invest Clin · Pubmed #29265118.

ABSTRACT: An Essay on the Shaking Palsy, by James Parkinson, was published in 1817. Later, Jean-Martin Charcot better described some of the motor features of the disease and named the condition as "La Maladie de Parkinson." As understanding about the disease progressed, aided by both clinical expertise and technological developments, the definition of what is Parkinson's disease has evolved. Motor phenotype, non-motor symptoms, monogenic mutations, genetic risk factors, disease subtyping, and data-driven clusters, among other concepts, have given rise to the hypothesis that Parkinson's disease may be not one well-defined entity but several different diseases encompassed as a levodopa-responsive Parkinsonism. This review present and discusses several of these factors and how they may support or not the notion of Parkinson's being one or more diseases. In summary, current evidence appears to be insufficient at this moment to clarify this issue. Parkinson's disease will continue to be an evolving concept over the years to come.

Next